Helminth-Associated Allergy: Current Management Guidelines

Background & Immunological Basis

• Massive polyclonal IgE elevation (total IgE often >1000 IU/mL)
• Peripheral and tissue eosinophilia — correlating with the degree of larval tissue migration (Harrison's, p. 6581)
• Th2 skewing via IL-4, IL-5, IL-13, and IL-25/IL-33/TSLP alarmins
• Regulatory T-cell induction (especially in chronic infection) — which can suppress atopic disease manifestations (the "hygiene/old friends hypothesis")

Clinical Syndromes with Allergic Features

Diagnostic Approach

1. Laboratory Evaluation

• Total serum IgE: markedly elevated (often >1000 IU/mL) in active tissue-migratory infection
• CBC with differential: eosinophil count (>500 cells/µL suspicious; >3000 severe)
• Specific IgE: e.g., anti-Anisakis IgE for fish-associated allergy/anaphylaxis
• Stool ova and parasites (×3 samples, different days) — sensitivity limited for Strongyloides
• Strongyloides serology (ELISA): sensitivity ~85–95% — preferred screening tool in at-risk individuals
• Toxocara serology: in children with asthma + eosinophilia
• Filarial antigen tests (e.g., Og4C3 circulating antigen for W. bancrofti)
• BAL/biopsy: when pulmonary eosinophilia or tissue diagnosis needed

2. Imaging

• Chest X-ray/CT: fleeting infiltrates (Löffler), nodules (paragonimiasis), bilateral reticulonodular pattern (tropical pulmonary eosinophilia)
• Abdominal ultrasound/CT: for visceral involvement (hepatic Toxocara, schistosomal fibrosis)

Management by Condition

General Principles

1. Treat the underlying helminth infection first — this is the definitive management of helminth-associated allergy
2. Symptomatic allergy management is adjunctive, not primary
3. Screen for and treat Strongyloides before any immunosuppression (especially corticosteroids), which can precipitate potentially fatal hyperinfection syndrome (Management of Glomerular Diseases, p. 104)

Anthelmintic Treatment by Pathogen

Management of Allergic Manifestations

Urticaria / Angioedema

• Antihistamines (non-sedating H1 blockers: cetirizine, loratadine, fexofenadine) — for symptomatic relief while anthelmintics take effect
• Short-course oral corticosteroids for severe urticaria — only after Strongyloides has been excluded/treated
• Epinephrine 0.3–0.5 mg IM for anaphylaxis (e.g., Anisakis-associated)

Eosinophilic Pulmonary Syndromes (Löffler / Tropical Pulmonary Eosinophilia)

• DEC for filarial etiology (TPE)
• Supportive care: bronchodilators, short-course corticosteroids if severe
• Corticosteroids alone (without anthelmintic coverage) risk Strongyloides hyperinfection

Helminth-Exacerbated Asthma

• Standard asthma therapy (ICS ± LABA) per GINA guidelines
• Anthelmintic treatment may improve asthma control in helminth-sensitized patients, particularly in endemic settings
• Evidence from RCTs (e.g., trials in Ecuador, Ethiopia) is mixed — some show benefit particularly in Ascaris-sensitized individuals

Anisakis-Associated Allergy (Fish-Parasite Allergy)

• Avoidance of raw/undercooked fish or squid
• Heating fish to ≥60°C for ≥1 minute or freezing at −20°C for ≥7 days destroys larvae
• Carry self-injectable epinephrine if prior anaphylaxis
• Specific allergen immunotherapy (AIT) to Anisakis is under investigation but not yet standard

Special Populations

Immunosuppressed Patients (transplant, HIV, biologics, steroids)

• Screen all at-risk individuals (born or lived in tropics/subtropics) for Strongyloides before immunosuppression
• Preferred screening: serology (ELISA) + stool exam
• If high-risk and urgent immunosuppression needed: empiric ivermectin 200 µg/kg/day ×2 days (Management of Glomerular Diseases, p. 104)
• Hyperinfection syndrome mortality can exceed 80% — prevention is critical

Pregnancy

• Most anthelmintics are deferred to second trimester when possible
• WHO recommends preventive chemotherapy (albendazole/mebendazole) in pregnancy in endemic areas from the 2nd trimester onward for STH infections
• Ivermectin: limited data — generally avoided in first trimester

Children

• WHO preventive chemotherapy targets school-age children (5–15 years) with albendazole 400 mg or mebendazole 500 mg annually or semi-annually in endemic areas
• Preschool children (1–4 years): albendazole 200 mg or mebendazole 500 mg in mass drug administration programs

Biologics in Helminth-Associated Severe Allergy

Important: Active helminth infection must be treated before initiating anti-IL-5 biologics, as helminth-driven eosinophilia serves a protective role against the parasite; suppressing it risks dissemination.

WHO Preventive Chemotherapy Strategy (2022–2030 Road Map)

• Soil-transmitted helminths (STH): annual or biannual albendazole/mebendazole for at-risk populations (school-age children, pre-school children, women of reproductive age, adults in high-prevalence settings)
• Lymphatic filariasis: annual mass drug administration (MDA) with DEC + albendazole or ivermectin + albendazole
• Onchocerciasis: biannual ivermectin MDA
• Schistosomiasis: annual praziquantel MDA in endemic communities
• Goal: elimination as a public health problem by 2030 for most NTDs

Key Take-Home Points

1. Treat the helminth — anthelmintic therapy is the cornerstone; symptomatic allergy management alone is insufficient
2. Always exclude/treat Strongyloides before corticosteroids or any immunosuppression
3. High total IgE and eosinophilia in a traveler/immigrant = helminth screen mandatory
4. Anisakis allergy requires fish avoidance + epinephrine prescription
5. Biologics targeting Th2 pathways should only be used after confirmed anthelmintic clearance
6. Follow WHO preventive chemotherapy schedules in endemic populations